Abstract: The present invention relates to a method for the in vitro diagnosis of the exclusion of acute coronary syndromes (ACS), consisting in associating the quantification of the concentration of at least one cardiac marker selected from troponin, CK-MB and myoglobin and the quantification of the concentration of D-dimers in a sample, and to the use of a reagent for quantifying the concentration of at least one of said cardiac markers and of a reagent for quantifying the concentration of D-dimers for the in vitro diagnosis of the exclusion of an acute coronary syndrome.

Abstract: The invention discloses compounds of the formula: where n is 1, or 2 to 200 in which case each recurring unit can be the same or different, B is a protected or unprotected base capable of Watson-Crick or of Hoogsteen pairing.

Abstract: Chiral peptide nucleic acids are provided which hybridise strongly with complementary nucleic acids and have potential as antigene and antisense agents and as tools in molecular biology. The compounds have the formulae. where n is 1 to 200, B is a protected or unprotected base, X may be OH, Y may be H, and R′ and R″, which are the same or different, are H, C1-C6 alkyl, aryl or aralkyl or R′ or R″, together the carbon atoms to which they are attached, form a cycloalkyl ring and protected derivatives thereof.

Abstract: Chiral peptide nucleic acids are provided which hybridise strongly with complementary nucleic acids and have potential as antigene and antisense agents and as tools in molecular biology. Compounds with cis-stereochemistry and based on proline and a spacer amino acid have structures (II), (III), where n is 1 or 2-200, B is a protected or unprotected base, R is H or alkyl, aralkyl or heteroaryl and may be substituted, X may be OH, and Y may be H.

Abstract: The invention discloses compounds of the formula: 1

Abstract: A compound of formula (I) or (II), wherein X is hydrogen, halogen, alkyl, aralkyl,aryloxy, arylalkoxy or alkoxy, Y is hydrogen, halogen, alkyl, aralkyl, aryloxy, arylalkoxy or alkoxy, or formula (a) wherein A and B are different and one of A and B is CH2 and the other is O, NH, or S or A and B are both CH2 or CH═, and Ra, Rb, and Rc are the same or different and are hydrogen, halogen, alkyl, alkoxy, aryloxy, aralkyl or arylalkoxy. R1 is hydrogen, and R2 is hydrogen, C1-C6 alkyl or aryl which is unsubstituted or substituted by halogen, cyano, hydroxy, C1-C6 alkyl, which is unsubstituted or substituted by halogen, cyano, hydroxy, C1-C6 alkoxy, aralkyl, aryloxy or aryl, C1-C6 alkoxy, aralkyl, arylalkoxy, aryloxy or aryl, which is unsubstituted or substituted by halogen, cyano, hydroxy, C1-C6 alkyl or C1-C6 alkoxy; and pharmaceutically acceptable salts thereof; with the proviso that when R2 is phenyl and Y is hydrogen, X is not chlorine.

Abstract: Chiral peptide nucleic acids are provided which hybridise strongly with complementary nucleic acids and have potential as antigene and antisense agents and as tools in molecular biology.

Abstract: The invention discloses compounds of the formula: 1

Abstract: Chiral peptide nucleic acids are provided which hybridise strongly with complementary nucleic acids and have potential as antigene and antisense agents and as tools in molecular biology. Compounds with cis-stereochemistry and based on proline and a spacer amino acid have structures (II), (III), where n is 1 or 2-200, B is a protected or unprotected base, R is H or alkyl, aralkyl or heteroaryl and may be substituted, X may be OH, and Y may be H.

Abstract: Chiral peptide nucleic acids are provided which hybridize strongly with complementary nucleic acids and have potential as antigene and antisense agents and as tools in molecular biology.

Abstract: A new class of 2,2′:6′,2″-terpyridine-platinum (II) and substituted 2,2′:6′,2″-terpyridine-platinum (II) complexes in which an N— or O— or halo nucleophile is the fourth ligand to platinum. The compounds are potent intercalators of DNA. Some have antitumour activity. Some have anti-parasitic activity. A new method of preparing the complexes involves reacting a Pt complex of 1,5-cyclooctadiene with a 2,2′:6′,2″-terpyridine.